Welcome to our dedicated page for Natera SEC filings (Ticker: NTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Natera, Inc. filings document the regulatory record for a Nasdaq-listed diagnostics company focused on cell-free DNA and precision medicine. Recent Form 8-K reports furnish results of operations and financial condition, press releases, investor presentations and exhibit information tied to quarterly and annual reporting.
The company’s proxy materials describe board composition, director elections, committee assignments, executive compensation, equity-award disclosures and stockholder voting matters. Its filings also identify the registered common stock class, Nasdaq Global Select Market listing, governance actions and other material-event disclosures relevant to Natera’s public-company reporting.
Morgan Stanley Smith Barney LLC submits a Form 144 notice listing 100,000 Common shares to be sold, described as proceeds from Previously Exercised Stock Options for cash, with an associated aggregate amount of $21,923,000. The filing also reports 10b5-1 sales by Matthew Rabinowitz of 75,000 and 50,000 Common shares on 03/13/2026 and 03/16/2026, respectively.
Natera, Inc. director Marcus Gail Boxer reported an exercise-and-sell transaction in company stock. On June 5, 2026, he exercised stock options for 11,000 shares of Common Stock at an exercise price of $22.83 per share and sold 11,000 shares in multiple open-market trades.
The sales were executed in several tranches at weighted average prices around $216–$219 per share, with detailed price ranges disclosed in the notes. Following these transactions, Boxer directly owns 6,183 shares of Natera Common Stock, and the option position related to these 11,000 shares is fully exercised.
Natera, Inc. filed an initial ownership report for Thomas J. Lynch Jr., who is identified as a director of the company. This Form 3 does not list any stock transactions or current holdings, and it confirms he is not classified as a ten percent owner based on this filing.
Natera, Inc. CEO and President Steven Leonard Chapman reported open-market sales of 41,124 shares of common stock on June 4, 2026. The 14 separate transactions were executed at weighted-average prices, with footnotes showing sale prices ranging from about $211.89 to $227.21 per share under a pre-arranged Rule 10b5-1 trading plan adopted and later amended by the reporting person. After these sales, Chapman continues to hold 149,035 shares of Natera common stock directly.
Natera, Inc. expanded its Board of Directors from eleven to twelve members and appointed Thomas Lynch as a new director, effective June 2, 2026. He will serve as a Class I director with a term running until the 2028 annual stockholder meeting and has been deemed independent under Nasdaq standards. Lynch will join the Board’s Human Capital Committee and receive cash and equity compensation in line with Natera’s existing non-employee director program. His initial equity award will vest in three equal installments on June 26 of 2027, 2028, and 2029. The company also plans to enter into an indemnification agreement with him and notes there are no family relationships or related-party transactions requiring disclosure.
Steven L. Chapman reported proposed and recent transactions in Common stock via a Form 144 filing. The filing lists multiple reported sales during the past three months: 5/4/2026: 909 shares for $189,283.07; 5/1/2026: 902 shares for $185,956.32; 4/29/2026: 3,352 shares for $649,909.13; 4/28/2026: 2,313 shares for $463,027.24; 4/27/2026: 5,838 shares for $1,191,774.74; and 3/10/2026: 5,623 shares for $1,147,838.17. The filing also references Restricted Stock with an original grant date of 01/21/2022.
Natera, Inc. president of clinical diagnostics Solomon Moshkevich sold 3,000 shares of common stock in open-market transactions. The trades on June 1, 2026 were executed under a pre-arranged Rule 10b5-1 trading plan and at various prices. After these sales, he directly holds 137,643 shares.
Rubin Eric H reported acquisition or exercise transactions in this Form 4 filing.
Natera, Inc. director Eric H. Rubin received a grant of 2,124 shares of Common Stock in the form of Restricted Stock Units as compensation. The award is valued at $425,000 and increases his direct holdings to 2,129 shares.
The RSUs will vest in three equal annual installments beginning on March 26, 2027. Each RSU represents a contingent right to receive one share of Natera’s Common Stock, so Rubin will receive the underlying shares over time as the units vest.
Natera, Inc. director Roelof Botha reported a series of open-market sales totaling 78,000 shares of Natera common stock on June 1, 2026, executed through estate planning vehicles. The reported weighted average sale prices ranged from about $218 to $224 per share across multiple trades. Following these transactions, estate planning vehicles associated with Botha held 1,127,787 shares indirectly, while he also reported 2,894 shares held directly.